Home -> Law Blog Directory -> Qui Tam Blogs -> Pharma 101 - Pharmaceutical Fraud

Qui Tam

: Pharma 101 - Pharmaceutical Fraud

GOVERNMENT CLARIFIES FCA?s USE AGAINST DECEPTIVE PHARMACEUTICAL MARKETING PRACTICES

From time to time, pharmaceutical companies have challenged the reach of the FCA, especially as it is applies to off-label pharmaceutical marketing schemes. Last week, the US Department of Justice weighed in on this debate, when it filed a Statement of Interest in an ongoing FCA case that alleges that Pfizer violated the FCA by off-label marketing its drug Lipitor. While not intervening in this qui tam action, the Justice Department submitted its Statement to clarify the legal basis for an FCA c read more

Full post as published by Pharma 101 - Pharmaceutical Fraud on October 11, 2010 (boomark / email).